Original Investigation

Human Genetics

, 125:281

First online:

Association of Y chromosome haplogroup I with HIV progression, and HAART outcome

  • Efe SezginAffiliated withLaboratory of Genomic Diversity
  • , Joanne M. LindAffiliated withLaboratory of Genomic DiversitySchool of Medicine, University of Western Sydney
  • , Sadeep ShresthaAffiliated withLaboratory of Genomic DiversityBasic Research Program, SAIC-Frederick, Inc.Department of Epidemiology and International Health, School of Public Health, University of Alabama
  • , Sher HendricksonAffiliated withLaboratory of Genomic Diversity
  • , James J. GoedertAffiliated withViral Epidemiology Branch, National Cancer Institute
  • , Sharyne DonfieldAffiliated withRho, Incorporated
  • , Gregory D. KirkAffiliated withDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health
  • , John P. PhairAffiliated withNorthwestern University Medical School, Comprehensive AIDS Center
  • , Jennifer L. TroyerAffiliated withLaboratory of Genomic DiversityBasic Research Program, SAIC-Frederick, Inc.
    • , Stephen J. O’BrienAffiliated withLaboratory of Genomic Diversity
    • , Michael W. SmithAffiliated withLaboratory of Genomic DiversityBasic Research Program, SAIC-Frederick, Inc.Genetics and Genomics, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The host genetic basis of differential outcomes in HIV infection, progression, viral load set point and highly active retroviral therapy (HAART) responses was examined for the common Y haplogroups in European Americans and African Americans. Accelerated progression to acquired immune deficiency syndrome (AIDS) and related death in European Americans among Y chromosome haplogroup I (Y-I) subjects was discovered. Additionally, Y-I haplogroup subjects on HAART took a longer time to HIV-1 viral suppression and were more likely to fail HAART. Both the accelerated progression and longer time to viral suppression results observed in haplogroup Y-I were significant after false-discovery-rate corrections. A higher frequency of AIDS-defining illnesses was also observed in haplogroup Y-I. These effects were independent of the previously identified autosomal AIDS restriction genes. When the Y-I haplogroup subjects were further subdivided into six I subhaplogroups, no one subhaplogroup accounted for the effects on HIV progression, viral load or HAART response. Adjustment of the analyses for population stratification found significant and concordant haplogroup Y-I results. The Y chromosome haplogroup analyses of HIV infection and progression in African Americans were not significant. Our results suggest that one or more loci on the Y chromosome found on haplogroup Y-I have an effect on AIDS progression and treatment responses in European Americans.